BioSpace News Archive

The Dow Chemical Company, a wholly-owned subsidiary of Dow Inc., announced the pricing terms of its previously-announced cash tender offers to purchase certain of its debt securities and certain debt securities of Union Carbide Corporation, a wholly-owned subsidiary of TDCC, listed in the table below in an aggregate purchase price of up to $550 million.

BD, a leading global medical technology company, announced that it will present at the following upcoming virtual investor healthcare conferences

Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) announce the signing of U.S. and French distribution partners for the Fionet Mobile COVID-19 testing and tracking platform.

MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization (CRO) is pleased to announce the expansion of its digital health and cybersecurity franchise.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 20 individuals hired by Sarepta in August 2020.

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine and potentially other addictions, today announced that the first subjects have begun dosing of EMB-001 in a Phase 2 study for cocaine use disorder.

Shattuck Labs, Inc. (“Shattuck”), an innovative clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC®) platform to develop an entirely new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced initiation of a Phase 1 clinical trial of its compound SL-172154 (SIRPα-Fc-CD40L)

Elektrofi, Inc., a Boston-based biotechnology company focused on drug formulation and delivery innovations, and LEO Pharma A/S, a global leader in medical dermatology, today announced an exclusive license agreement to develop subcutaneously administered antibodies using Elektrofi’s high-concentration, low-volume delivery technology.

Maverick Therapeutics, Inc., a private biopharmaceutical company pioneering conditionally active bispecific T cell targeted immunotherapies, today announced the promotion of Jeremiah Degenhardt, Ph.D. to Vice President, Translational Oncology & Bioinformatics, as well as the appointment of three immuno-oncology experts to its Scientific Advisory Board.

Relias, a trusted education and training partner to more than 11,000 healthcare clients, was recognized by the Triangle Business Journal (TBJ) as a winner of its 2020 Leaders in Diversity Award.